LFD-200

LFD-200 is a novel antibody-drug conjugate (ADC) developed by Lifordi Immunotherapeutics for the treatment of autoimmune and inflammatory diseases. The drug consists of an anti-VISTA antibody conjugated to a modified budesonide payload, with a drug-antibody ratio (DAR) of eight. Upon binding to V-domain Ig suppressor of T cell activation (VISTA) on immune cells, the ADC is rapidly internalized; inside the cell, budesonide is released and binds to glucocorticoid receptors, modulating inflammatory gene expression in the nucleus. This targeted delivery aims to retain high efficacy typical of glucocorticoids while reducing systemic side effects associated with traditional steroid therapy. Preclinical studies have demonstrated dose-dependent efficacy in rheumatoid arthritis models and favorable pharmacokinetics supporting reduced toxicity and less frequent dosing[1][3][4][5].